Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
The Russian drugmaker R-Pharm has reached an agreement with French pharma company Servier on the localization of drugs for the treatment of socially significant diseases at its facilities in Azerbaijan, a former Soviet state and one of the most economically developed countries in the South Caucasus region. 27 July 2021
Shares of UK-based medicinal cannabis firm Kanabo Group were up 9.6% at 16.44 pence early afternoon today, after it announced the proposed acquisition of the European businesses of 11157353 Canada Corp, which trades under the name of Materia. 26 July 2021
Italian specialty pharma company Cassiopea today announced the signing of license and supply agreements with India’s Sun Pharmaceutical Industries for Winlevi (clascoterone cream 1%) in the USA and Canada. 26 July 2021
Some digital health tools are becoming integral parts of mainstream medicine, according to findings released today by the IQVIA Institute for Human Data Science in a new report. 23 July 2021
As a result of its July meetings, the European Medicines Agency’s Committee for Medicinal Products for Human has recommended just two novel medicines for approval and rejected one. 23 July 2021
The US Food and Drug Administration yesterday approved Bydureon and Bydureon BCie (exenatide extended-release) injection to be used in addition to diet and exercise to improve glycemic control (blood sugar levels) in pediatric patients 10 years or older with type 2 diabetes. 23 July 2021
GlaxoSmithKline has confirmed the current head of its consumer health joint venture (JV) will continue as chief executive once the unit is spun out into a standalone business. 23 July 2021
“In an increasingly globalized world, the exchange of knowledge is crucial for the pharmaceutical industry,” said Nelson Mussolini, Sindusfarma’s chairman. 23 July 2021
The European Commission has short-listed 11 new projects worth 120 million euros ($140 million) from Horizon Europe, the biggest European research and innovation program (2021-2027), for supporting and enabling urgent research into the coronavirus and its variants. 23 July 2021
National Health Service (NHS) patients in England are set to benefit from early access to potentially life-saving new medicines, including cutting-edge gene therapies, thanks to a new Innovative Medicines Fund and £680 million ($925 million) of ringfenced funding, the NHS chief executive has announced today. 21 July 2021
Novartis saw its share edge up 2.1% to 85.12 Swiss francs in early trading, after the Swiss pharma giant posted financial results for the second quarter of 2021 that beat expectations. 21 July 2021
USA-based healthcare giant Johnson & Johnson, together with three major drug distributors, are ready to agree to a $26 billion settlement in connection with lawsuits over the ongoing opioid epidemic. 21 July 2021
The European Commission (EC) has approved the marketing authorization application for Ryeqo (relugolix 40mg, estradiol 1.0mg, and norethindrone acetate 0.5mg) for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, with no limitation for duration of use. 21 July 2021
The US Food and Drug Administration has approved fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness (Human African trypanosomiasis) in patients six years of age and older and weighing at least 20 kg. 21 July 2021
An Expert View on the pros and cons of intellectual property (IP) protections in the pharmaceutical sector from White & Case partners' competition lawyer, James Killick, chair of the firm’s IP practice, Anita Varma, and associate and member of the Global Competition practice group, Alexander Krois. 20 July 2021